secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2024-09-27T23:59:59+00:00
Accession:  0000950170-24-109998
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences reports Gemini induces dose-dependent IL-10 increases up to 309-fold in Phase 1
--------------------------------------------------------------------------------

- Gemini induced statistically significant (p<0.05) dose-dependent IL-10 increases: 27-fold (low), 162-fold (mid), 309-fold (high) vs placebo at 2 hours.
- No significant increase in pro-inflammatory IL-1b and TNF-a, confirming TLR4 binding unique to Gemini.
- Data consistent with prior preclinical acute kidney injury models; supports potential in preventing AKI after cardiac surgery.
- Company plans to initiate Phase 1b study in late 2024.
- CEO James Rolke highlighted potential to fine-tune innate immune response and speed healing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017024109998/0000950170-24-109998-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017024109998/revb-20240924.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-109998

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer